2,3-dihydro-6-methoxy-1H-indene-1-acetic acid ethyl ester | 91284-09-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2,3-dihydro-6-methoxy-1H-indene-1-acetic acid ethyl ester
• 英文别名: ethyl 2-(6'-methoxy-2',3'-dihydro-1'H-inden-1'-yl)acetate；ethyl (6-methoxyindan-1-yl)acetate；(6-Methoxy-indan-1yl)-acetic acid ethyl ester；ethyl 2-(6-methoxy-2,3-dihydro-1H-inden-1-yl)acetate
• CAS: 91284-09-2
• 化学式: C₁₄H₁₈O₃
• 分子量: 234.295
• InChiKey: JFLBIJJMEVSLDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,3-dihydro-6-methoxy-1H-indene-1-acetic acid ethyl ester 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以97.6%的产率得到2,3-二氢-6-甲氧基-1H-茚-1-乙酸
  参考文献：
  名称：

  Synthesis of novel molecular probes inspired by harringtonolide

  摘要：

  一个受哈灵顿烯启发的新型骨架，包含一个环七烯环和两个融合的环戊烷环，已从简单的起始材料合成。该骨架具有与复杂的二萜类相似的取代模式和相对立体化学，并已被扩展为一小型衍生物库。这个库中的一个成员已通过铜催化的叠氮-三键环加成（点击）化学转化为一个取代类三唑的子库。该骨架可能在药物发现中或用于制备额外的化学生物学分子探针方面具有应用潜力。

  DOI：

  10.1039/c1ob05299c
• 作为产物：
  描述：

  6-甲氧基-1-茚酮 在 Pd-C 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 以64%的产率得到2,3-dihydro-6-methoxy-1H-indene-1-acetic acid ethyl ester
  参考文献：
  名称：

  Benzocycloalkene compounds, their production and use

  摘要：

  式中R1和R2为H、一个碳氢基团或一个杂环基团，或者R1和R2合并为一个螺环；R3为一个碳氢基团、一个取代氨基团、一个取代羟基团或一个杂环基团；R4为H或烷基；环A为一个取代苯环；m和n表示1到4；{overscore (.........)}表示一个单键或双键或盐，一种生产方法及具有对褪黑激素受体具有结合亲和力的组合物。

  公开号：

  US06235789B1

文献信息

• Compounds that modulate PPAR activity and methods of preparation
  申请人：——

  公开号：US20030207915A1

  公开（公告）日：2003-11-06

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

  这项发明揭示了能够改变PPAR活性的化合物。该发明还揭示了这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。本发明还揭示了制备所述化合物的方法。
• Sulfonyl-substituted bicyclic compounds as modulators of PPAR
  申请人：Noble A. Stewart

  公开号：US20060167012A1

  公开（公告）日：2006-07-27

  Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

  本发明揭示了作为过氧化物酶体增殖物激活受体的调节剂的化合物，包括这些化合物的制药组合物以及使用它们治疗疾病的方法。
• SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
  申请人：Noble Stewart A.

  公开号：US20090227599A1

  公开（公告）日：2009-09-10

  Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

  本发明揭示了化合物作为过氧化物酶体增殖物活化受体的调节剂，以及包含该化合物的制药组合物和使用该化合物治疗疾病的方法。
• WO2008/106179
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists
  作者：Kohji Fukatsu、Osamu Uchikawa、Mitsuru Kawada、Toru Yamano、Masayuki Yamashita、Koki Kato、Keisuke Hirai、Shuji Hinuma、Masaomi Miyamoto、Shigenori Ohkawa

  DOI：10.1021/jm020114g

  日期：2002.9.1

  We synthesized a novel series of benzocycloalkene derivatives and evaluated their binding affinities to melatonin receptors. To control the spatial position of the amide group, one of the important pharmacophores, we incorporated an endo double bond, an exo double bond (E- and Z-configurations), and a chiral center (R- and S-configurations) at position 1. The indan derivatives with the S-configuration at position 1 were the most promising in terms of potency and selectivity for the human melatonin receptor (MT, site), while compounds with the R-configuration showed little potential. Our next attempt was to investigate the most favorable conformation of the methoxy group, the other important pharmacophore for binding to the MT, receptor. The introduction of a methyl group at position 5 of the indene ring conserved affinity; however, at position 7, it caused a decrease in affinity. These results suggested that the substitution at position 7 forced the methoxy group to adopt an unfavorable orientation. The optimization of the condensed ring size and substituents led to (S)-8d [(S)-N-[2-(2,3-dihydro-6-methoxy-1H-inden-1-yl)ethyl]propionamide], which had high affinity for the human MT3 receptor (K-i = 0.041 nM) but no significant affinity for the hamster MT3 receptor (K-i = 3570 nM). In addition, a practical synthetic method of chiral N-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]-alkanamides employing asymmetric hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru has been established.